Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 19;13:2042. doi: 10.1038/s41467-022-29625-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Association between rs143348853 and cancer risk based on information from the Finnish cancer registry (FinnGen GWAS study). b Association between rs143348853 deletion carrier status (ref/ref vs. ref/alt + alt/alt) and event-free survival (EFS) probability in CLL. Data was obtained from the ICGC CLLE-ES project^27,35. P-values are based on log-rank tests for the two groups and the probability of 10-year EFS is indicated. c Same as b but considering the <65-year-old M-CLL patients only. d Same as b but for the UNIUPO CLL cohort and considering the low-risk (wild-type TP53) M-CLL patients only. e Meta-analysis of the rs143348853-EFS-hazard ratios for M-CLL patients obtained from a Cox proportional hazards regression model. f Experimental design for the in vivo competition assay between MEC1-ctr and MEC1-AXIN2 cells. g Fold change of the final cell percentage (day 26) relative to the input percentage (day 0) of MEC1-AXIN2 mCherry + or MEC1-ctr GFP + cells from the in vivo competition experiment; the mean across all 20 mice is displayed, p-value calculated with a paired two-sided t-test. Source data are provided as a Source Data file. n and P indicate the number of considered patients and p-value, respectively.